Drugs / CTL119
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04419909 | May 2026 → Jul 2028 expected | B-cell non-Hodgkin lymphoma | University of Pennsylvania | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CTL119 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04419909 ↗ |
| Modality | Cell therapy | “chimeric antigen receptor (CAR) modified T cells” NCT04419909 ↗ |
| Target | CD19 | “huCD19-directed Chimeric Antigen Receptor-modified T Cells” NCT04419909 ↗ |